Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy
M Fontana, JL Berk, JD Gillmore… - … England Journal of …, 2024 - discovery.ucl.ac.uk
BACKGROUND: Transthyretin amyloidosis with cardiomyopathy (ATTR-CM) is a
progressive, fatal disease. Vutrisiran, a subcutaneously administered RNA interference …
progressive, fatal disease. Vutrisiran, a subcutaneously administered RNA interference …
Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies
WJ Sandborn, S Vermeire, L Peyrin-Biroulet… - The Lancet, 2023 - thelancet.com
Background Etrasimod, a once-daily, oral, sphingosine 1-phosphate (S1P) receptor
modulator that selectively activates S1P receptor subtypes 1, 4, and 5, with no detectable …
modulator that selectively activates S1P receptor subtypes 1, 4, and 5, with no detectable …
Multiplicity considerations in clinical trials
A Dmitrienko, RB D'Agostino Sr - New England Journal of …, 2018 - Mass Medical Soc
Multiplicity Considerations in Clinical Trials | New England Journal of Medicine Skip to main
content The New England Journal of Medicine homepage Advanced Search SEARCH …
content The New England Journal of Medicine homepage Advanced Search SEARCH …
Efficacy and safety of fixed-dose esketamine nasal spray combined with a new oral antidepressant in treatment-resistant depression: results of a randomized, double …
M Fedgchin, M Trivedi, EJ Daly… - International Journal …, 2019 - academic.oup.com
Background About one-third of patients with depression fail to achieve remission despite
treatment with multiple antidepressants and are considered to have treatment-resistant …
treatment with multiple antidepressants and are considered to have treatment-resistant …
Aerobic or resistance exercise, or both, in dieting obese older adults
DT Villareal, L Aguirre, AB Gurney… - … England Journal of …, 2017 - Mass Medical Soc
Background Obesity causes frailty in older adults; however, weight loss might accelerate
age-related loss of muscle and bone mass and resultant sarcopenia and osteopenia …
age-related loss of muscle and bone mass and resultant sarcopenia and osteopenia …
Key multiplicity issues in clinical drug development
A Dmitrienko, RB D'Agostino Sr… - Statistics in …, 2013 - Wiley Online Library
Much progress has been made over the past decade with the development of novel
methods for addressing increasingly more complex multiplicity problems arising in …
methods for addressing increasingly more complex multiplicity problems arising in …
Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3)
G Umpierrez, S Tofé Povedano, F Pérez Manghi… - Diabetes …, 2014 - Am Diabetes Assoc
OBJECTIVE Compare the efficacy and safety of monotherapy with dulaglutide, a once-
weekly GLP-1 receptor agonist, to metformin-treated patients with type 2 diabetes. The …
weekly GLP-1 receptor agonist, to metformin-treated patients with type 2 diabetes. The …
Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial
AR Tan, GS Wright, AR Thummala, MA Danso… - The lancet …, 2019 - thelancet.com
Background Trilaciclib is an intravenous cell-cycle inhibitor that transiently maintains
immune cells and haemopoietic stem and progenitor cells in G1 arrest. By protecting the …
immune cells and haemopoietic stem and progenitor cells in G1 arrest. By protecting the …
Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensive‐stage small cell lung cancer: a multicentre, randomised, double‐blind …
D Daniel, V Kuchava, I Bondarenko… - … journal of cancer, 2021 - Wiley Online Library
Trilaciclib is an intravenous CDK4/6 inhibitor administered prior to chemotherapy to
preserve haematopoietic stem and progenitor cells and immune system function from …
preserve haematopoietic stem and progenitor cells and immune system function from …
Initial combination therapy with canagliflozin plus metformin versus each component as monotherapy for drug-naive type 2 diabetes
J Rosenstock, L Chuck, M González-Ortiz… - Diabetes …, 2016 - Am Diabetes Assoc
OBJECTIVE This study assessed the efficacy/safety of canagliflozin (CANA), a sodium–
glucose cotransporter 2 (SGLT2) inhibitor, plus metformin extended-release (MET) initial …
glucose cotransporter 2 (SGLT2) inhibitor, plus metformin extended-release (MET) initial …